Four first-class new drugs of Haizheng Pharmaceutical Co., Ltd. have successfully carried out clinical trials in the United States and China

Among them, the world's second cholesterol absorption inhibitor, hazel mAb, has completed phase I clinical research in the United States and is conducting phase II clinical research, which is expected to end by the end of the year; meanwhile, it has obtained phase II / III clinical research approval documents in China According to the company, the reproductive toxicity and long-term toxicity of hezemab are lower than those of ezemeb of Merck pharmaceutical The international sales of the former's single and compound medicines reached 4.3 billion US dollars in 2012 In addition, HPPH, the third generation photosensitizer, has completed the I/II phase clinical trial of esophageal cancer and non small cell cancer and the I phase clinical study of head and neck cancer in the United States, and is preparing to carry out the III phase clinical study; in China, it has obtained the approval of I/II/III phase clinical study in June, and is expected to complete the clinical study and apply for production in 2017 The new Alzheimer's drug AD35 has been approved by the US ind application in July this year; the domestic application for phase I clinical application has been completed in 2013, and the supplementary information is currently being supplemented It is expected that Q1 in 2015 will be approved In 2013, ginsenoside c-k, a new traditional Chinese medicine for rheumatoid arthritis, has obtained phase I clinical approval, and the single clinical administration experiment is in progress It is expected to complete multiple administration and declare phase II clinical application in 2015 Haizheng Pharmaceutical Co., Ltd.: biological medicine mainly focuses on monoclonal antibody and insulin, and six of the top ten drugs in the world have been developed According to the person in charge of biological medicine business of Haizheng Pharmaceutical Co., Ltd., the company's biological medicine sector has rich variety reserves, many of which have obtained clinical approval, started phase I clinical trials, and will submit five new drug applications (ind) in the second half of this year According to the person in charge, the first expected variety in the field of biological drugs - ambenol (recombinant human tumor necrosis factor II receptor antibody fusion protein for injection) is undergoing on-site verification and GMP two in one inspection, and is expected to be launched at the end of this year and the beginning of next year In terms of insulin, the second generation of recombinant human insulin and protamine insulin have started the first phase of clinical practice, while the third generation of recombinant glargine insulin and recombinant aspart insulin have submitted clinical applications In addition, Haizheng Pharmaceutical Co., Ltd has also submitted the domestic clinical application of adamumumab, patozumab and other international heavyweight varieties The preparation business is growing rapidly The head of the domestic preparation business of Haizheng pharmaceutical industry, which is led by Hepatology and orthopedic drugs, said that the domestic preparation of the company has grown rapidly in the past three years Among them, the first imitation drug in the field of liver disease treatment, ximexin (ademetionine succinate for injection), glucosamine sulfate, Tongluo Shenggu Capsule, etc., will become a large variety Data shows that the sales volume of ximexin reached 110 million yuan in the first half of 2014, compared with only 166 million yuan in the whole year of last year The company expects that the drug will become a large variety with sales volume of more than one billion yuan in 2018 In the first half of this year, the sales of glucosamine sulfate and Tongluoshenggu Capsule reached 66 million yuan and 14 million yuan respectively, with a significant year-on-year growth According to the above person in charge, the generic drugs the company plans to list in the next three years include the cardiovascular drug rosuvastatin, the high-end antibiotics daptomycin, teicoplanin, the immunosuppressant sirolimus, the antineoplastic drugs penstatin, bortezomib, etc.